One Nucleus: Seasoned Director

One Nucleus, the Cambridge-based not-for-profit membership organisation for international life science and healthcare companies, announced the appointment of Linda Summerton as a Director. Summerton is Chief Executive of Immodulon and a Senior Partner with TranScrip Partners.

Read more

Vifor Pharma expands ChemoCentryx partnership

Swiss Galenica subsidiary Vifor Pharma has licensed commercialisation rights for ChemoCentryx Inc’s complement C5a receptor (C5aR ) blocker Avacopan (CCX168) in Asia and the Middle East. The drug is currently undergoing Phase III testing in patients with rare renal diseases.

Read more

Novimmune partners with LegoChem Biosciences

Swiss antibody specialist Novimmune has entered a R&D collaboration on antibody drug conjugates (ADC) with the South Korean conjugation chemistry expert LegoChem Biosciences.

Read more

Oncoinvent closes US$25m private placement

After having issued a patent on its lead cancer treatment Radspherin, Oslo-based Oncoinvent A/S has bagged the funding needed to go ahead to proof-of-concept.

Read more

AMR: EU Commission awards €45,000

Vytenis Andriukaitis, Commissioner for Health and Food Safety, has awarded the EU Health Award for NGOs fighting Antimicrobial Resistance to BEUC for lobbying to reduce the threat of antimicrobial resistance (AMR). 

Read more

Prexton Therapeutics gets €29m cash injection

Merck Serono spin-out Prexton Therapeutics has closed a Series B financing round cashing in US$31m for pushing Phase II testing of its Parkinson’s compound PXT002331.

Read more

Biotechs concerned over EPO rules

Life Sciences stakeholders in Europe and abroad are voicing their concerns about the European Patent Offices’ initiative to shorten the time for the examination of patents from up to 56 months to 12 months. 

Read more

Medherant: Chair for the clinic

University of Warwick spin-out Medherant Ltd has appointed Ken Cunningham as its chair right in time for the company’s move into the clinical development of its novel transdermal drug delivery patch technology. Cunningham is already Chairman of Abzena as well as Non-Executive Director of Verona Pharma plc. 
Read more

Biotech investor plans IPO in London

British life science investor Arix Biosciences is planning an IPO at London Stock Exchange. The London-based investor aims to raise £100m (€116m) to reinvest in innovations in medical science.
Read more

Prize awarded to innovative products

In early February, at the 20th edition of the Pharmapack Europe event, outstanding products were honoured with the Pharmapack Award. Organiser UBM EMEA also introduced a new Pharmapack Start-up Hub.
Read more